Form D · Other Technology
Prellis Biologics, Inc
Hayward, CA · CIK 0001711459
Offering snapshot reported Jul 6, 2022 · SEC filing
- Reported sold
- $17M Offering amount: $35M
- Investors reported
- 19 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 22, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 6, 2022 | Initial | $17,000,000 | No comparison | 19 | SEC filing |
| Jul 14, 2021 | Initial | $19,252,758 | No comparison | 9 | SEC filing |
| Mar 27, 2019 | Initial | $8,741,168 | No comparison | 11 | SEC filing |
| Feb 2, 2018 | Initial | $460,000 | No comparison | 2 | SEC filing |
| Jul 10, 2017 | Initial | $1,849,999 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-451265
Source: Form D, filed Jul 6, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Arvind Gupta | Director |
| Shaun Holt | Director |
| Michael Marks | Director |
| Melanie Matheu | Director, Executive |
| Lei Meng | Director |
| Alex Morgan | Director |
| Noelle Mullin | Director, Executive |
| Sean O'sullivan | Director |
| Rohit Sharma | Director |
Issuer details
Industry: Other Technology (See others in industry)
Address:
3944 Trust Way
Hayward, CA, 94545
Hayward, CA, 94545